Investors Urged to Act as Pomerantz Law Firm Investigates Capricor Therapeutics Claims

Investigation of Capricor Therapeutics, Inc. by Pomerantz Law Firm

The Pomerantz Law Firm has initiated an investigation into claims on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR), focusing on allegations of potential securities fraud by the company and its management. Capricor, known for its innovative therapies, particularly in the realm of Duchenne muscular dystrophy (DMD), recently faced backlash following significant stock price fluctuations tied to company announcements and regulatory developments.

On May 5, 2025, the company issued a press release regarding the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) concerning Capricor's Biologics License Application (BLA) for deramiocel, an investigational therapy aimed at treating DMD cardiomyopathy. This announcement initially raised investor optimism; however, the stock began to decline sharply on the following day. It fell by $3.00 per share (29.13%), closing at $7.30, reflecting investor concerns over the regulatory future of deramiocel.

The difficulties intensified when, on June 20, 2025, a report from STAT revealed that the new head of the FDA's relevant unit canceled the advisory committee meeting intended to evaluate deramiocel due to unspecified concerns over the drug's efficacy and safety. Following this report, Capricor's stock dropped again, falling by $3.68 per share (30.82%), closing at $8.26.

These dramatic shifts in Capricor's stock price, seemingly correlated with pivotal corporate events and regulatory news, have prompted Pomerantz to investigate whether the actions of Capricor executives constituted violations of securities laws or were indicative of broader business misconduct. Investors who feel they may be affected by these developments are encouraged to reach out to attorney Danielle Peyton at Pomerantz for further information.

Pomerantz, recognized as a top-tier firm specializing in corporate and securities class litigation, has a long history of advocating for investors' rights. Given the firm's track record, the investigation into Capricor represents an important opportunity for affected investors to potentially seek recourse related to their investment losses.

The outcome of this investigation could have significant implications not only for Capricor and its stakeholders but also for the broader biotechnology sector facing similar scrutiny over the efficacy and safety of emerging treatments. Stakeholders in the biotech field and investment community are advised to follow developments closely and to consider engaging with legal professionals to understand their options.

For more information about the Capricor investigation or to participate in any potential class action, interested investors should contact Pomerantz LLP directly at the number listed in their press release or through their official website, where further updates will be posted as the investigation progresses.

In conclusion, the unfolding story of Capricor Therapeutics encapsulates the volatile nature of the biotechnology sector, where news can impact stock valuations dramatically, revealing the essential role that legal scrutiny and diligent representation play in maintaining market integrity and investor confidence.